Associated tags: Medicine, OGM, Patient, Spectrum, Biology, Genome, Software, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest.
Key Points:
- SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest.
- Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.
Medicine,
FISH,
Augusta University,
National Health Service,
Workflow,
Genomics,
KT,
NGS,
National Comprehensive Cancer Network,
Karyotype,
NCCN,
MDS,
Patient,
SAN,
NHS,
OGM,
Gene,
VIA,
Software,
Medical imaging,
Cancer SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.
Key Points:
- SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.
- The study describes myeloid cancers as posing a significant challenge to manage, with approximately 50% of cases displaying cytogenetically normal genomes, which can confound traditional analysis approaches.
- In this blinded retrospective analysis of samples from 30 myeloid cancer subjects, the combination of OGM with the 523-gene NGS panel was compared to the common approach of KT and FISH combined with a 54-gene NGS panel.
- A pre-commercial version of Bionano’s new NxClinical™ software enabled analysis of OGM and NGS data together, providing an integrated picture of genomic variation.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.
Key Points:
- SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.
- The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting.
- “We appreciate the support of our stockholders on these critically important proxy proposals,” said Erik Holmlin, Ph.D., president and chief executive officer of Bionano.
- “We now look forward to continuing to execute upon our strategy.”
ISSCR,
Genomics,
National Institutes of Health,
Research,
Immortalised cell line,
Regenerative medicine,
SAN,
International Society for Stem Cell Research,
OGM,
NIH,
International Society,
Safety,
Medical device ISSCR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine.
Key Points:
- ISSCR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine.
- The ISSCR conference will be held June 14-17, 2023, online and in-person in Boston, Massachusetts.
- Presentations will cover OGM’s utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing.
- A scientific poster by Dr. Andy Pang from Bionano, covering the use of OGM in cell manufacturing and bioprocessing applications, will be on display during the conference.
Hospital for Sick Children,
Lymphoma,
Duke University,
Research Triangle,
Central nervous system,
ALL,
Acute lymphoblastic leukemia,
Cutaneous T-cell lymphoma,
Stanford University,
CTCL,
Genomics,
Pathology,
Cancer,
SVS,
Prognosis,
Research,
Infection,
Biomarker,
Doctor of Philosophy,
CNS,
Creativity,
Drug resistance,
Patient,
The Hospital,
SAN,
Neoplasm,
Hospital,
Health,
OGM,
DSM-IV codes,
Bone marrow,
Medical imaging,
Vaccine,
Pharmaceutical industry Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.
Key Points:
- Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.
- Bionano’s Innovator Research program was established to fuel novel research using the company’s OGM products to detect relevant structural variants (SVs), demonstrating OGM’s potential to advance discoveries and innovation in ways that may elevate health and wellness for all people.
- The Bionano Innovator Research Grant will enable us to resolve structural variants as they arise during treatment and to determine their role in drug resistance.
- The Bionano Innovator Research Grant program was established to attract applicants with projects that demonstrate exemplary vision and creativity in leveraging OGM and genomic technologies to tackle complex challenges.
Immortalised cell line,
Cell,
MH,
Genetics,
Acute lymphoblastic leukemia,
Ibis,
Cancer,
Research,
DSM-IV codes,
CHU,
Gene editing,
Radbod,
UZ Leuven,
EHA,
European Central Bank,
OGM,
Bone marrow,
Medical device,
Online shopping Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.
Key Points:
- Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.
- “Researchers and scientists continue to push forward cutting-edge research in the human genetics space, and we are pleased to see them share their findings with conference attendees.
- These presentations point to the continued expansion of OGM into clinical research applications for cancer, genetic disease and cell therapy where we believe OGM has the potential to deliver significant advantages relative to the current methodologies.”
For more information on EHA, please visit https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .
- For more information on ESHG, please visit https://bionano.com/eshg2023/ .
Tissue,
DNA,
G2,
HRD,
Genomics,
NGS,
ITP,
RNA,
Doctor of Philosophy,
Isotachophoresis,
Chemistry,
Dicarboxylic acid,
SAN,
UHMW,
OGM,
Ionic,
Phosphorus SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.
Key Points:
- SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.
- Most clinical samples used in oncology research are stored as FFPE tissues, which often contain degraded or fragmented nucleic acid.
- Conventional extraction methods are labor intensive and can further damage nucleic acid during the extraction and purification process.
- The Ionic® G2 chemistry includes four new kits for use with the Ionic Purification System, including G2 FFPE to DNA, G2 FFPE to RNA, G2 FFPE Complete and G2 Tissue to DNA.
HRD,
Genomics,
GAAP,
Curie Institute (Paris),
Doctor of Philosophy,
Acquisition,
Investment,
Risk,
DSM-IV codes,
Bone marrow,
University,
NGS,
Spectrum,
Mosaic,
Research,
Whole genome sequencing,
LRS,
Children's Hospital Los Angeles,
WGS,
Growth,
Hospital,
OEM,
OGM,
NMPA,
Trisomy,
Total,
BGPT,
MRKH,
DNA,
Workflow,
Cancer,
SOC,
Publication,
Genetic disorder,
Standard of care,
University of Toronto,
ASD,
SAN,
National Medical Products Administration,
IVD,
MD Anderson Cancer Center,
Acceleration,
Toronto,
SVS,
Sale,
NVIDIA,
Female,
Breast cancer,
Mobile phone,
Video game,
Medical device,
Pharmaceutical industry,
Dietary supplement,
Renewable energy,
Augusta University GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.
Key Points:
- GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.
- First quarter 2023 non-GAAP¹ gross margin was 30%, compared to 15% from the first quarter of 2022.
- First quarter 2023 GAAP operating expense was $39.9 million, compared to $30.8 million in the first quarter of 2022.
- First quarter 2023 non-GAAP operating expense was $33.6 million, compared to $24.2 million in the first quarter of 2022.
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.
Key Points:
- SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.
Key Points:
- The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023 , on June 14, 2023, at 10:00 a.m. Pacific Time.
- Stockholders of record as of April 24, 2023, may vote at the annual meeting or by proxy over the telephone, through the internet or using the Notice of Internet Availability of Proxy Materials mailed to such stockholders.
- Stockholders may change their vote at any time before the final vote at the annual meeting.
- Details regarding voting procedures are included in the Company’s proxy statement for the annual meeting, filed with the U.S. Securities and Exchange Commission on April 28, 2023.
